Our pipeline

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers.

 

Our medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval.

 

The content of our development pipeline will change over time as new projects progress from research to development and from development to the market.

 

For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.

 

Brand names are trademarks either owned by and/or licensed to GSK or associated companies.

 

This quarterly pipeline information was updated on 30 October 2019.

 

Download full pipeline in XLSX

XLSX - 16.5KB

Key

In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.

MAA and NDA/BLA regulatory review milestones shown in the table below are those that have been achieved. Future filing dates are not included in this list.

Pipeline last updated on 30 October 2019

  • Additional indication
  • Immuno-modulator

Key

In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.

MAA and NDA/BLA regulatory review milestones shown in the table below are those that have been achieved. Future filing dates are not included in this list.

Pipeline changes from Q2 2019 to Q3 2019

Key

In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.

MAA and NDA/BLA regulatory review milestones shown in the table below are those that have been achieved. Future filing dates are not included in this list.

  • Additional indication
  • Immuno-modulator